Difficulty: Medium
Average Score: 94%
Practice
Which of the following is not a good prognostic factor in patient with acute lymphoblastic leukemia?
Correct answer
A
Rationale
In patients with acute lymphoblastic leukemia (ALL), understanding prognostic factors is crucial for treatment planning and predicting outcomes. The correct answer is A) Immunophenotype - mature B cell. This is not a good prognostic factor because ALL originating from mature B cells tends to have a poorer prognosis compared to other subtypes.
Option B) Gender - female is not the correct answer because being female is actually associated with a better prognosis in ALL due to hormonal and genetic factors. Option C) Chromosomal number - hyperploidy is a good prognostic factor in ALL as it is often associated with a more favorable outcome. Option D) Age - 4 to 10 years old is also a good prognostic factor as children in this age range generally respond better to treatment and have a higher survival rate.
Educationally, understanding prognostic factors in hematologic malignancies like ALL is essential for healthcare professionals involved in the care of these patients. Recognizing the impact of factors such as immunophenotype, gender, chromosomal abnormalities, and age on prognosis helps tailor treatment strategies and improve patient outcomes. It underscores the importance of personalized medicine in oncology and highlights the need for ongoing research to refine risk stratification in ALL.
Option B) Gender - female is not the correct answer because being female is actually associated with a better prognosis in ALL due to hormonal and genetic factors. Option C) Chromosomal number - hyperploidy is a good prognostic factor in ALL as it is often associated with a more favorable outcome. Option D) Age - 4 to 10 years old is also a good prognostic factor as children in this age range generally respond better to treatment and have a higher survival rate.
Educationally, understanding prognostic factors in hematologic malignancies like ALL is essential for healthcare professionals involved in the care of these patients. Recognizing the impact of factors such as immunophenotype, gender, chromosomal abnormalities, and age on prognosis helps tailor treatment strategies and improve patient outcomes. It underscores the importance of personalized medicine in oncology and highlights the need for ongoing research to refine risk stratification in ALL.